| Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. | |
| | |
MedLine Citation:
|
PMID: 16403850 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS). DATA SOURCES: Clinical literature was accessed through MEDLINE (1966-August 2005), Science Citation Index (1980-August 2005), and Proceedings of the American Society of Hematology (2000-2004). DATA SYNTHESIS: New analogs of thalidomide have been synthesized that are more potent and less toxic. Lenalidomide (CC-5013) is currently in Phase III trials for the treatment of multiple myeloma and MDS. Phase II trials demonstrated lenalidomide's efficacy in patients refractory to thalidomide. The full potential of this agent has yet to be proven, but preliminary data seem promising. CONCLUSIONS: Lenalidomide is a potent immunomodulating drug that offers different mechanisms of action and therapeutic potential for the treatment of multiple myeloma, MDS, and other malignancies. |
| | |
Authors:
|
Sara K Maier; Julia M Hammond |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-01-10 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 40 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2006 Feb |
Date Detail:
|
Created Date: 2006-02-07 Completed Date: 2006-03-31 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 286-9 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy, Duke University Medical Center, Durham, NC 27710-3089, USA. sara.maier@duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials as Topic Humans Immunologic Factors / therapeutic use* MEDLINE Multiple Myeloma / drug therapy*, immunology Myelodysplastic Syndromes / drug therapy*, immunology Thalidomide / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Immunologic Factors; 191732-72-6/lenalidomide; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current status of cetuximab for the treatment of patients with solid tumors.
Next Document: Emerging treatments for bipolar disorder: safety and adverse effect profiles.